Human Integrin beta 2/CD18 Alexa Fluor® 350-conjugated Antibody Summary
Accession # AAA59490
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
Background: Integrin beta 2/CD18
Integrin alpha X beta 2, also called CD11c/CD18, p150/95 or complement receptor type 4 (CR4), is one of four beta 2 integrins. The non-covalent heterodimer of 150 kDa alpha X/CD11c and 95 kDa beta 2/CD18 integrin subunits is expressed on macrophages, dendritic cells and hairy cell leukemias, with lower amounts on other myeloid cells and activated B, NK and some cytotoxic T cells (1‑7). Like other integrins, alpha X beta 2 has multiple activation states (3). In the presence of divalent cations and "inside-out" signaling, alpha X beta 2 is fully active and extended. The alpha X vWFA or I-domain, which contains the adhesion sites, forms the N-terminal head region with the alpha X beta-propeller and the beta 2 vWFA domain (1, 8). In the inactive state, the heterodimer flexes in the center at the alpha X thigh and calf domains and beta 2 I-EGF domains, impeding access to adhesion sites (1). The 1088 aa human alpha X/CD11c ECD shares 70‑76% aa sequence identity with mouse, rat and canine alpha X while the 678 aa human beta 2/CD18 ECD shares 81‑83% aa sequence identity with mouse, rat, cow, dog, goat, sheep, and pig beta 2. Potential alpha X isoforms containing 719 and 725 aa (as compared to full-length 1163 aa alpha X) lack the vWFA domain and the N-terminus. Active alpha X beta 2 shares some adhesion partners with alpha M beta 2/CD11b/CD18, including complement opsonin fragment iC3b, ICAMs, vWF and fibrinogen, and is expressed on many of the same cells (4‑11). However, alpha M beta 2 activity is often constitutive, while alpha X beta 2 activity requires cell activation (4‑7). alpha X beta 2 also binds osteopontin, Thy-1, plasminogen, heparin, and proteins with abnormally exposed acidic residues (11‑16). The adhesion events are important for proliferation, degranulation, chemotactic migration, and phagocytosis of complement-opsonized particles (5, 6, 9, 11, 12, 16). Mutations of beta 2, especially in the vWFA domain, cause leukocyte adhesion deficiency (LAD-1) and susceptibility to bacterial infections (17).
- Corbi, A.L. et al. (1987) EMBO J. 6:4023.
- Kishimoto, T.K. et al. (1987) Cell 48:681.
- Hynes, R.O. (2002) Cell 110:673.
- Arnaout, M.A. (1990) Blood 75:1037.
- Postigo, A.A. et al. (1991) J. Exp. Med. 174:1313.
- Beyer, M. et al. (2005) Respir. Res. 6:70.
- Nicolaou, F. et al. (2003) Blood 101:4033.
- Vorup-Jensen, T. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1873.
- Bilsland, C.A.G. et al. (1994) J. Immunol. 152:4582.
- Pendu, R. et al. (2006) Blood 108:3746.
- Sadhu, C. et al. (2007) J. Leukoc. Biol. 81:1395.
- Schack, L. et al. (2009) J. Immunol. 182:6943.
- Choi, J. et al. (2005) Biochem. Biophys. Res. Commun. 331:557.
- Gang, J. et al. (2007) Mol. Cells 24:240.
- Vorup-Jensen, T. et al. (2007) J. Biol. Chem. 282:30869.
- Vorup-Jensen, T. et al. (2004) Proc. Natl. Acad. Sci. USA 102:1614.
- Kishimoto, T.K. et al. (1987) Cell 50:193.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human Integrin beta 2/CD18 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human Integrin beta 2/CD18 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human Integrin beta 2/CD18 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image